Crizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with severe, sometim
Respiration status of complex I, II+III, and IV of the ETC was evaluated in fresh left ventricular tissue as described in the Materials and Methods. According to oxygen flux measures (pmol/mg/substrat
